Search Results 591-600 of 15724 for 3-day reset protocol

  1. Study of TL-895 in Subjects With Myelofibrosis - Mayo Clinic

    Sponsor Protocol Number: TL-895-201. About this ... Cohorts 1-3 ... (Day -7 to Day -1) score of at least 1 for each of the 2 symptoms per MFSAF v4.0 * Cohort 3 ...

  2. Gastroenterology and Hepatology - Clinical trials

    Hyperplastic polyps are common but they have a low malignancy potential (3). There is evidence that colonic inflammation plays a major role in colon polyp and ...

  3. PROCEDURE,PROCEDURE RECORD NAME,UNIT CHARGE,UNIT ... PROCEDURE LEVEL 5,50,50, 300000265,HC MPL ... 3,1899,1899, 300000421,HC 2D6 SEQUENCING +4,2404 ...

  4. Mayo Clinic Minute: Signs that stress is becoming toxic

    With a new year right around the corner, it might be time to reset when it comes to your mental health. ... Small amounts of stress can motivate you to face daily ...

  5. Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma - Mayo Clinic

    Phase 3 trials include large numbers of people to ... Sponsor Protocol Number: NU13S02 ... Major surgical procedure, open biopsy, or significant traumatic injury ...

  6. Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170) - Mayo Clinic

    Phase 3 trials include large numbers of people to ... Sponsor Protocol Number: MK-3475-170-01 ... Day 1 or prior radiation therapy within 4 weeks prior to study Day ...

  7. A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants with Smoldering Multiple Myeloma - Mayo Clinic

    Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines ...

  8. Randomized Trial Comparing Immediate vs. Deferred Surgery for Symptomatic ERM (Protocol AM) - Mayo Clinic

    Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

  9. Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination with Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer - Mayo Clinic

    Subjects will receive dabrafenib 150 mg twice daily (BID) in monotherapy treatment and dabrafenib 150 mg bid and trametinib 2 mg once daily in combination ...

  10. Clinical trials - Oncology (Medical)

    ... 3-4 weeks, and at 3-6 months) cognitive function ... The aim of this study is to study the efficacy and safety of our short and long one-day ... protocol for early ...